The accurate knowledge of CFTR (cystic fibrosis Transmembrane conductance regulator) mutations is of obvious interest in clinical testing, as it improves CF prevention programs of neonatal screening, heterozygote screening in partners of CF patients or partners of carriers. This evidence concerns the gene CFTR and cystic fibrosis.